Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in pediatric refractory/relapsed solid tumors and lymphoma
NCT03451825Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Mar 2018
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 1, open-label trial of avelumab in solid tumor and lymphoma (2 arms), sponsored by EMD Serono. Primary endpoints: Treatment-Emergent Adverse Events and Dose-Limiting Toxicities. Started Mar 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03451825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451825.